Chapter 1 λ Toxicology
ANTIDOTES
Table XI-1-3. Summary of Antidotes
Antidote |
|
Type of Poisoning |
Acetylcysteine |
|
Acetaminophen |
Atropine + pralidoxime |
|
AChE inhibitors—physostigmine, neostigmine, and |
(for irreversible AChE |
|
pyridostigmine; organophosphates, including |
inhibitors) |
|
insecticides, such as malathion and parathion |
Deferoxamine |
|
Iron and iron salts |
Digoxin immune F(ab) |
|
Digoxin |
Dimercaprol (BAL) |
|
Arsenic, gold, mercury, lead; oral succimer for milder |
|
|
lead and mercury toxicity |
EDTA |
|
Backup in lead poisoning, then for rarer toxicities |
|
|
(Cd, Cr, Co, Mn, Zn) |
Esmolol |
|
Theophylline, beta agonists |
Ethanol, fomepizole |
|
Methanol or ethylene glycol |
Flumazenil |
|
Benzodiazepines, zolpidem, zaleplon |
Naloxone |
|
Opioid analgesics |
Oxygen |
|
Carbon monoxide |
Penicillamine |
|
Copper (e.g., Wilson’s disease), iron, lead, mercury |
Physostigmine |
|
Anticholinergics: atropine, antihistamine, |
|
|
antiparkinsonian—not tricyclics |
Protamine |
|
Heparins |
Vitamin K |
|
Warfarin and coumarin anticoagulants |
Activated charcoal |
|
Nonspecific: all oral poisonings except Fe, CN, Li, |
|
|
solvents, mineral acids, or corrosives |
317
Section XI λ Toxicology
NATURAL MEDICINALS
“Natural” medicinals are available without prescription and are considered to be nutritional supplements rather than drugs. Herbal (botanic) products are marketed without FDA review of safety and efficacy, and there are no requirements governing the purity or the chemical identities of constituents. Evidence supporting the clinical effectiveness of herbal products is commonly incomplete.
Table XI-1-4. Characteristics of Selected Herbals
|
|
|
|
Possible |
|
|
Name |
|
Medicinal Use(s) |
|
Mechanism(s) |
|
Side Effects |
Echinacea |
|
↓ Cold symptoms |
↑ ILs and TNF |
GI distress, |
||
|
|
|
|
|
|
dizziness, |
|
|
|
|
|
headache |
|
Garlic |
Hyperlipidemias, |
Inhibits HMG-CoA |
Allergies, |
|||
|
cancer (evidence is |
reductase and |
hypotension, |
|||
|
weak) |
ACE |
antiplatelet actions; |
|||
|
|
|
|
|
use caution |
|
|
|
|
|
|
when used with |
|
|
|
|
|
|
anticoagulants |
|
Gingko |
Intermittent |
Antioxidant, free |
Anxiety, GI distress, |
|||
|
claudication; |
radical scavenger, |
insomnia, |
|||
|
Alzheimer disease |
↑ NO |
antiplatelet actions; |
|||
|
(evidence is weak) |
|
|
use caution when |
||
|
|
|
|
|
used with |
|
|
|
|
|
|
anticoagulants |
|
Ginseng |
Possible ↑ in |
Unknown |
Insomnia, |
|||
|
mental and physical |
|
|
nervousness, |
||
|
performance |
|
|
hypertension, |
||
|
(evidence is weak) |
|
|
mastalgia, vaginal |
||
|
|
|
|
|
bleeding |
|
Saw |
Symptomatic |
5α-reductase |
GI pain, decreased |
|||
palmetto |
treatment of BPH |
inhibitor and |
libido, headache, |
|||
|
|
|
androgen |
hypertension |
||
|
|
|
receptor |
|
|
|
|
|
|
antagonist |
|
|
|
St. John’s |
Depressive disorder |
May enhance |
Major drug |
|||
wort |
(variable evidence for |
brain 5HT |
interactions: |
|||
|
clinical efficacy) |
functions |
serotonin syndrome |
|||
|
|
|
|
|
with SSRIs; induces |
|
|
|
|
|
|
P450, leading to ↓ |
|
|
|
|
|
|
effects of multiple |
|
|
|
|
|
|
drugs |
|
318